Skip to main content
Log in

ABSORB III: Mehr Infarkte nach bioresorbierbarem Scaffold im Langzeitverlauf

ABSORB III: more infarcts after bioresorbable scaffolds in the long-term course

  • Journal Club
  • Published:
Der Kardiologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Serruys PW, Chevalier B, Sotomi Y et al (2016) Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3-year, randomized, controlled, single-blind, multicenter trial. Lancet 388(10059):2479–2491. doi:10.1016/s0140-6736(16)32050-5

    Article  CAS  PubMed  Google Scholar 

  2. Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C, Stone GW, ABSORB III Investigators (2015) Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med 373(20):1905–1915

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to H. Eggebrecht.

Ethics declarations

Interessenkonflikt

H. Eggebrecht gibt an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eggebrecht, H. ABSORB III: Mehr Infarkte nach bioresorbierbarem Scaffold im Langzeitverlauf. Kardiologe 11, 250–252 (2017). https://doi.org/10.1007/s12181-017-0145-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12181-017-0145-1

Navigation